Non-Small Cell Lung Cancer (NSCLC) Market Report 2026

The non-small cell lung cancer (nsclc) market size has grown rapidly in recent years. It will grow from $42.2 billion in 2025 to $46.65 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to high prevalence of smoking, exposure to air pollution, late-stage diagnosis, limited targeted therapy options, reliance on conventional chemotherapy.

The non-small cell lung cancer (nsclc) market size is expected to see rapid growth in the next few years. It will grow to $70.81 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to rising adoption of targeted therapies and immunotherapy, increasing investment in lung cancer diagnostics, growth of personalized medicine, expansion of oncology centers and specialty clinics, development of ai-based predictive models and imaging solutions. Major trends in the forecast period include rising adoption of targeted therapy and immunotherapy, increasing use of advanced radiotherapy techniques, growing implementation of laser therapy and photodynamic therapy, expanding deployment of early diagnosis and screening programs, advancing integration of ai-powered imaging and predictive oncology.

The rising rate of tobacco consumption is expected to drive the growth of the non-small cell lung cancer (NSCLC) market in the coming years. Tobacco consumption, through smoking, chewing, or snuffing, introduces nicotine and multiple carcinogens into the body, which can damage DNA in lung cells, triggering mutations and the uncontrolled growth of cancerous cells, including NSCLC. Factors such as the popularity of smoking among youth and the availability of various tobacco products contribute to this trend. For instance, in October 2024, according to the 2024 National Youth Tobacco Survey published by the U.S. Food and Drug Administration (USFDA), approximately 2.25 million students (1.1%) reported current use of tobacco products, with 1.58 million high school students (10.1%) and 640,000 middle school students (5.4%) using tobacco. Additionally, 760,000 students (2.8%) reported using any combustible tobacco product, while 840,000 students (3%) reported using multiple tobacco products. Therefore, the increasing tobacco consumption is fueling NSCLC market growth.

Major companies in the NSCLC market are focusing on developing targeted therapies, supported by FDA accelerated approvals, to expand treatment options for patients. FDA accelerated approval allows earlier access to therapies that target specific molecular or genetic abnormalities based on surrogate or intermediate endpoints likely to predict clinical benefit. For instance, in July 2025, Dizal (Jiangsu) Pharmaceutical Co., Ltd., a China-based biotechnology company, launched sunvozertinib (Zegfrovy) for adults with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. Administered orally at 200 mg once daily with food until disease progression or unacceptable toxicity, Zegfrovy demonstrated a 46% confirmed overall response rate and an 11.1-month duration of response in the WU-KONG1B trial. The FDA approval also included the Oncomine Dx Express Test as a companion diagnostic. Sunvozertinib carries warnings for interstitial lung disease, gastrointestinal and dermatologic reactions, ocular toxicity, and embryo-fetal toxicity.

In December 2023, Pfizer Inc., a US-based biopharmaceutical company, acquired Seagen for approximately $43 billion. This strategic acquisition aims to strengthen Pfizer’s oncology pipeline, particularly in NSCLC, by leveraging Seagen’s expertise in antibody-drug conjugate (ADC) technology to develop next-generation cancer therapies. Seagen is a US-based biotechnology company actively developing and studying therapies for NSCLC.

Major companies operating in the non-small cell lung cancer (nsclc) market are Pfizer Inc., F. Hoffmann‑La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Clovis Oncology, Revolution Medicines, Boehringer Ingelheim GmbH, Johnson & Johnson, Daiichi Sankyo Company Limited, BeiGene Ltd., DualityBio, Gilead Sciences Inc., Mirati Therapeutics Inc., Arcus Biosciences Inc., NeoImmuneTech.

North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (nsclc) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-small cell lung cancer (nsclc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the non-small cell lung cancer market by increasing costs of imported targeted therapy drugs, laser and photodynamic therapy equipment, and radiotherapy devices. Segments such as radiotherapy, laser therapy, and immunotherapy are most affected, with north america, europe, and asia-pacific experiencing the highest cost pressures. While tariffs have raised procurement costs and lead times, they also encourage domestic manufacturing, drive innovation in cost-effective oncology treatments, and strengthen regional healthcare supply chains.

The non-small cell lung cancer (nsclc) market research report is one of a series of new reports that provides non-small cell lung cancer (nsclc) market statistics, including non-small cell lung cancer (nsclc) industry global market size, regional shares, competitors with a non-small cell lung cancer (nsclc) market share, detailed non-small cell lung cancer (nsclc) market segments, market trends and opportunities, and any further data you may need to thrive in the non-small cell lung cancer (nsclc) industry. This non-small cell lung cancer (nsclc) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Non-small cell lung cancer (NSCLC) is a type of epithelial lung cancer that develops in lung tissues and is characterized by abnormal cell growth. Major risk factors include long-term smoking, genetic mutations, air pollution, and exposure to secondhand smoke.

The primary types of non-small cell lung cancer include squamous cell carcinoma, large cell carcinoma, adenocarcinoma, and others. Squamous cell carcinoma originates from squamous epithelial cells and can also develop in other parts of the body. Treatment options include radiotherapy, laser therapy, photodynamic therapy (PDT), and others, with distribution channels such as hospital pharmacies, online pharmacies, and additional outlets.

The non-small cell lung cancer (NSCLC) market includes revenues earned by entities by providing services such as targeted therapies, radiation therapies, imaging tests, biopsy, bronchoscopy, and lung function tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-small cell lung cancer (NSCLC) market also includes sales of chemotherapy drugs such as cisplatin, carboplatin, and pemetrexed epidermal growth factor receptor (EGFR) inhibitors such as erlotinib, afatinib, and gefitinib, as well as pain medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.